Quick Answer
Denali Therapeutics Inc. reported Common Stock Shares Outstanding of 156.18 million shares for the year ending 2025.
- Denali Therapeutics Inc. showed an increase of +8.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: 92.59 million shares | Q2 2018: 93.32 million shares | Q3 2018: 93.97 million shares | Q1 2019: 95.26 million shares | Q2 2019: 95.66 million shares | Q3 2019: 95.99 million shares | Q1 2020: 105.54 million shares | Q2 2020: 105.90 million shares | Q3 2020: 119.80 million shares | Q1 2021: 121.15 million shares | Q2 2021: 121.53 million shares | Q3 2021: 122.01 million shares | Q1 2022: 122.86 million shares | Q2 2022: 123.16 million shares | Q3 2022: 123.80 million shares | Q1 2023: 136.74 million shares | Q2 2023: 137.36 million shares | Q3 2023: 138.05 million shares | Q1 2024: 142.51 million shares | Q2 2024: 143.12 million shares | Q3 2024: 143.84 million shares | Q1 2025: 145.25 million shares | Q2 2025: 145.69 million shares | Q3 2025: 146.63 million shares.
- Over the full 9 years of available data (2017 to 2025), Denali Therapeutics Inc.'s Common Stock Shares Outstanding has grown by 78.5%.
- Historical annual values: Fiscal year 2025: 156.18 million shares | Fiscal year 2024: 144.22 million shares | Fiscal year 2023: 138.39 million shares | Fiscal year 2022: 135.97 million shares | Fiscal year 2021: 122.28 million shares | Fiscal year 2020: 120.53 million shares | Fiscal year 2019: 96.19 million shares | Fiscal year 2018: 94.66 million shares | Fiscal year 2017: 87.48 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: